淄博风湿病应注意什么菏泽怎样治疗{风湿}比较好,滨州治疗骨关节炎哪家医院比较好,济宁哪里有治疗月子病的神医,聊城济南哪家风湿医院比较好,济宁出了月子走路脚特别疼怎么办,青岛全国好的风湿性关节炎医院是那家,潍坊生姜治月子病

BEIJING, Oct. 1 (Xinhua) -- China plans to decrease leprosy rates by 50 percent over the next 10 years, according to a joint plan to fight the infectious disease issued by the Ministry of Health and ten other ministerial-level institutions.The prevalence rate is targeted to be brought down to one case per 10,000 people by 2015. The rate will further shrink to one in every 100,000 people by 2020 in at least 98 percent of the country's counties, according to the plan.A total of 500,000 cases of leprosy have been reported and treated for free throughout the country since the founding of the People's Republic of China on Oct. 1, 1949.The number of leprosy cases has plummeted over the past 62 years, but the country still faces challenges in fighting the disease, the plan said.Leprosy, an infectious disease that has affected humanity for over 4,000 years, is primarily characterized by skin lesions and progressive physical debility, and can cause permanent nerve damage.Despite sustained efforts -- and considerable success -- in bringing the disease under control, leprosy is still a serious disease in some parts of China and people who have been cured of the disease continue to face discrimination.More than 1,700 new cases have been reported annually in the past five years. The provinces of Sichuan, Yunnan, Guizhou and Hunan and the Tibet Autonomous Region are most affected by the disease, according to the plan.

BEIJING, Nov. 27 (Xinhua) -- China's industrial enterprises saw their profits increase 25.3 percent year-on-year in the first ten months of 2011, slowing down from the year's previously recorded figures, official data showed Sunday.Growth in the January-October period was 1.7 percentage points lower from that of the first three quarters, the National Bureau of Statistics (NBS) said in a statement.It marked a gradual downshift from the 34.3-percent year-on-year growth seen during the January-February period and the 28.7-percent growth seen during the first half of the year.Profits realized in the first ten months amounted to 4.12 trillion yuan (650 billion U.S. dollars), the NBS said.The NBS compiled the figures using data collected from a pool of industrial businesses with at least 20 million yuan in annual sales revenues each.In October alone, industrial profits expanded 12.5 percent year-on-year to 438.3 billion yuan, the NBS said.Among 39 industries surveyed, 36 sectors reported profit growth in the first ten months. The oil refining, coking and nuclear-fuel processing sector saw profit plunge 89.8 percent year-on-year.Private businesses posted the fastest profit growth, with a year-on-year rise of 44.3 percent, followed by collectively owned enterprises of 33 percent, equity-holding companies of 30.3 percent, state-owned enterprises of 16.6 percent and overseas-funded firms of 11.6 percent.China's industrial production growth rate will moderate due to economic turmoil in Europe and the United States and weakening domestic demand brought about by a tightened monetary policy, Huang Libin, an official with the Ministry of Industry and Information Technology, said last week.China saw its economic growth slow to 9.1 percent in the third quarter of this year from 9.5 percent in the second quarter and 9.7 percent in the first quarter.

SAN FRANCISCO, Jan. 12 (Xinhua) -- Microsoft on Thursday announced a patent licensing agreement with LG Electronics covering the South Korean manufacturer's tablets, smartphones and other consumer devices running Google's Android or Chrome operating system.In a press release, Microsoft said it marks the 11th deal with a device manufacturer leveraging Google's operating system platform, noting that "more than 70 percent of all Android smartphones in the U.S. are now receiving coverage under Microsoft 's patent portfolio."Terms of the deal were not disclosed. So far, Microsoft has struck major cross-licensing patent agreements with HTC, Samsung and Acer, among others.Last September, Microsoft announced a broad patent deal with Samsung. U.S. media reports cited South Korean media as saying that Microsoft had wanted Samsung to pay 10 to 15 U.S. dollars for each Android device.The booming mobile market has been harassed by acrimonious legal battles over patent infringement. Being an open source operating system, Google's Android has become a major target of patent suits.Microsoft has been going after companies that make phones and tablets running Android, rather than directly against Google. But the two tech giants are still engaged in public spats over the issue after Google's top legal officer posted a scathing blog last August accusing Microsoft and other companies of waging "a hostile, organized campaign against Android."Motorola Mobility, which Google announced to acquire in a 12.5 billion-dollar deal last August, currently is the last major Android device vendor that refuses to take a license from Microsoft.Frank Shaw, Microsoft's head of communications, used Twitter to taunt Google on Thursday, twitting "Hey Google -- we are the 70 percent" with a link to their press release.Brad Smith, Microsoft's executive vice president and general counsel, also tweeted "it's time to recognize that in patent world, lawsuits are the 1 percent; license agreements are the 99 percent. "Google so far has made no comments on the Microsoft-LG patent deal.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."

BEIJING, Dec. 14 (Xinhua) -- The People's Bank of China, the country's central bank, said Wednesday that China will continue its prudent monetary policy next year while making the policy more targeted, flexible and forward-looking.The announcement came after the conclusion of the annual central economic work conference Wednesday morning, which has set economic policy guidelines for the coming year.The central bank will maintain control over the intensity, pace and focus of macroeconomic regulation, make full use of monetary tools, tune up credit supply and promote reasonable growth in social financing, according to a statement posted on its website.The bank will improve credit structure, increase support to key sectors and weak areas, especially to agriculture, small and medium-sized enterprises and affordable housing construction, as well as better serve the real economy.It will continue to perfect its yuan exchange rate formation mechanism, and keep the yuan exchange rates basically stable at a reasonable and balanced level.Meanwhile, the bank will strengthen and improve its foreign exchange management, deepen financial system reforms, prevent and solve financial risks, the statement said.